

Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF- κ B Signaling Pathway to Attenuate Vascular Remodeling [LETTER]

Agriani Dini Pasiana¹, Hasta Handayani Idrus¹, Istianah Purnamasari²

¹Centre for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Bogor, West Java, Indonesia; ²Department of Pharmacy, Faculty of Medicine and Health Science, Universitas Muhammadiyah Makassar, Makassar, South Sulawesi, Indonesia

Correspondence: Agriani Dini Pasiana, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Jl. Raya Jakarta - Bogor Km. 46, Cibinong, Bogor, Jawa Barat, Indonesia, Email agrianipasiana@yahoo.com

Dear editor

We have read the article by Liu et al about Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF- κ B Signaling Pathway to Attenuate Vascular Remodeling. The purpose of this study was to identify the inhibitory effect of Forsythoside B (FTS•B) on the NF- κ B signaling pathway. Pulmonary arterial hypertension (PAH) is a serious pathological disease with limited effective treatment options. The proliferation of pulmonary artery smooth muscle cells (PASMCs) is induced by the activation of the nuclear factor- κ B (NF- κ B) signaling pathway which plays a crucial role in the pathogenesis of PAH.¹ Forsythoside B (FTS•B) is a phenylethanoid glycoside known for its effect to effectively activate nuclear factor erythroid 2-related factor 2 (Nrf2) to exert antioxidant and anti-inflammatory effects, it serves as a means of alleviating myocardial ischemia-reperfusion injury and suppressing the activation of endogenous inflammatory factors by inhibition of nuclear factor-kappa B (NF- κ B) signaling.²

Based on the methodological details given, they induced PAH condition with monocrotaline (MCT) intraperitoneal injection and measured the right ventricular hypertrophy using echocardiography and right heart catheterization.¹ Jasenovec et al confirmed the well-known effects of monocrotaline administration on the lungs and the right ventricle, as well as pulmonary arterial pressure. Additionally, they also discovered the activation of the alternative pathway of the renin-angiotensin system, specifically an increase in angiotensin (Ang) 1–7 and Ang 1–5, along with an increase in Ang I, but without any change in Ang II levels. Furthermore, there was a downregulation of aldosterone observed 4 weeks after monocrotaline administration.³ Phorbol 12-myristate 13-acetate (PMA) is a potent phorbol ester known for its effect on activating NF- κ B. It is a specific activator of Protein Kinase C (PKC) and hence activates nuclear factor-kappa B (NF- κ B). The nuclear factor kappa B (NF- κ B) is responsible for regulating genes involved in inflammation and immune responses. NF- κ B might be important in cardiovascular diseases (CVDs), atherosclerosis, and diabetes. It is reported that several therapeutic agents such as pimobendan and sodium–glucose cotransporter 2 inhibitors used for CVDs and diabetes, have anti-inflammatory effects by inhibiting NF- κ B activation; anti-inflammatory therapy may have beneficial effects in CVDs and diabetes.⁴

Based on the results, the FTS•B decreased the effect of MCT in vascular remodeling and pulmonary artery pressure and also improved right ventricular hypertrophy and survival. Moreover, FTS•B reversed PDGF-BB-induced PASMC proliferation and migration, decreased PCNA and CyclinD1 expression, and decreased levels of IL-1 β , IL-6, and phosphorylation of p65 caused by MCT.¹ In addition, FTS•B exerts neuroprotective effects by modulating various pathways, including oxidative stress, anti-inflammation, NF- κ B signaling, 2-AG, Nrf2 signaling, acetylcholinesterase,

PI3K-Akt signaling, ferroptosis, gut-brain axis, TLR4 signaling, endoplasmic reticulum stress, PI3K/Akt/mTOR signaling, and PPAR γ signaling pathway.⁵

We acknowledge and appreciate the findings obtained from the research. This study could serve as a model for better understanding the effect of FTS•B on impaired PAH by suppressing the NF- κ B signaling pathway to attenuate vascular remodeling. They also show that FTS•B might serve as an alternative medicine for PAH treatment.

Acknowledgments

The authors would like to acknowledge all the researchers and Prof. Dr. Sunarno in the Center for Biomedical Research BRIN for his continuous support. The authors would also like to convey gratitude to the research team of Liu et al for their valuable research report.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Liu J, Fang G, Lan C, et al. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF- κ B Signaling Pathway to Attenuate Vascular Remodeling. *Drug Des Devel Ther.* 2024;18:767–780. doi:10.2147/DDDT.S444605
2. Xia M, Zhang Y, Wu H, et al. Forsythoside B attenuates neuro-inflammation and neuronal apoptosis by inhibition of NF- κ B and p38-MAPK signaling pathways through activating Nrf2 post spinal cord injury. *Int Immunopharmacol.* 2022;111:109120. doi:10.1016/j.intimp.2022.109120
3. Jasenovec T, Radosinska D, Kollarova M, et al. Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: focus on Plasma and Erythrocyte Parameters. *Pharmaceuticals.* 2022;15(10):1227. doi:10.3390/ph15101227
4. Matsumori A. Nuclear Factor- κ B is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. *Eur Cardiol Rev.* 2023;18:e40. doi:10.15420/ecr.2023.10
5. Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: from mechanisms to treatment (Review). *Int J Mol Med.* 2022;49(2):15. doi:10.3892/ijmm.2021.5070

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S470685>